Author of

• 16831

  +

  P1.06 - Poster Session with Presenters Present (ID 458)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 2
  • Moderators:
  • Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 16844

    +

    P1.06-013 - Patient Characteristics and Survival: A Real-World Analysis of US Veterans With Stage IV Adenocarcinoma vs Squamous NSCLC (ID 4737)

    14:30 - 15:45  |  Author(s): P. Georgantopoulos
    • Abstract

    Background:
    5-year survival rate in patients with stage IV NSCLC was 1%. Stage IV adenocarcinoma (ADENO) and squamous (SCC) account for 44% and 18% of stage IV NSCLC diagnoses, respectively. Patient characteristics and survival in US veterans with stage IV ADENO vs SCC NSCLC were examined.
    
    Methods:
    Patients with a unique diagnosis of stage IV NSCLC between 1/1/2010 and 12/31/2015 from the US Veterans Affairs (VA) health system database were included. Lung cancer diagnoses were confirmed by VA Central Cancer Registry and Veterans Health Administration National Patient Care Database. Patients were excluded if they did not have 1 VA visit within 1 year before diagnosis.
    
    Results:
    13,956 patients with stage IV NSCLC were included (ADENO: n=6525 [47%]; SCC: n=3421 [25%]). Baseline characteristics were similar for ADENO vs SCC, including age at diagnosis (mean, 68.8 vs 69.2 y), married at diagnosis (43.9% vs 42.2%), had known Agent Orange exposure (17.4% vs 16.3%), and the majority were white (60.8% vs 63.8%). For ADENO vs SCC, more patients were former smokers (39.5% vs 34.3%), but fewer were current smokers (53.9% vs 61.1%). For ADENO vs SCC, occurrence of brain or bone metastases were higher and incidence of chronic obstructive pulmonary disease or chronic pulmonary disease were lower (Table); age at death (mean, 69.3 vs 69.7 y) and time from diagnosis to death (TDD; mean, 0.56 vs 0.55 y) were similar. More ADENO vs SCC patients received chemotherapy (48.5% vs 44.1%). Mean TDD was longer in patients treated with chemotherapy vs not (ADENO: 0.86 vs 0.31 y; SCC: 0.84 vs 0.35 y).Figure 1
    
    
    
    Conclusion:
    ADENO was more prevalent than SCC in veterans with stage IV NSCLC, similar to the overall population; stage IV SCC prevalence was higher in the veterans than in the overall population. Mean TDD was longer in chemotherapy-treated patients regardless of histology.
    
    

  • 16851

    +

    P1.06-020 - Prevalence of Autoimmune Disease in US Veterans With Non-Small Cell Lung Cancer (NSCLC) (ID 4745)

    14:30 - 15:45  |  Author(s): P. Georgantopoulos
    • Abstract

    Background:
    Immunotherapy has emerged as an effective treatment strategy in cancer; patients with preexisting autoimmune diseases are often restricted from use. The prevalence of autoimmune disease was 12.5% worldwide (Lerner, Int J of Celiac Disease, 2015) and 24.6% in US patients with lung cancer (LC) (Khan, JAMA Oncol 2016). We report autoimmune disease prevalence in veterans with NSCLC in a real-world setting.
    
    Methods:
    Patients with a unique diagnosis of NSCLC between 1/1/2010 and 12/31/2015 were included. Diagnoses were confirmed by VA Central Cancer Registry and Veterans Health Administration National Patient Care Database. Patients were excluded if they had <1 VA visit within 1 year prior to diagnosis. Baseline autoimmune diseases were identified using ICD-9 codes for 36 organ-specific and 7 systemic autoimmune diseases. Autoimmune disease was defined as having ≥1 claim of any type (broad definition) or having ≥1 inpatient claim or ≥2 outpatient claims ≥30 days apart (narrow definition).
    
    Results:
    40,371 patients with NSCLC were included (stage IV adenocarcinoma n=6525, stage IV squamous cell carcinoma (SCC) n=3421). Almost all patients were male (99.9%). Autoimmune disease prevalence was greater per broad vs narrow definition in all patients (15.7% vs 13.6%), adenocarcinoma patients (13.4% vs 11.0%), and SCC patients (15.0% vs 12.3%). By broad definition, 13.4% of all patients, 11.7% of patients with stage IV adenocarcinoma, and 13.0% of patients with stage IV SCC had 1 autoimmune disease; 2.3%, 1.7% and 2.0% had >1 autoimmune disease, respectively. The most common autoimmune diseases in all 3 patient populations were psoriasis, chronic rheumatic heart disease (CRHD), rheumatoid arthritis (RA), Addison disease, and ulcerative colitis (Table).Figure 1
    
    
    
    Conclusion:
    Prevalence of autoimmune disease was lower in the predominantly male US veterans with NSCLC than the general population with LC; the prevalence was similar regardless of stage or histology. The most frequent autoimmune diseases were psoriasis, CRHD, and RA.